NAVB Navidea Biopharmaceuticals Inc.

0.74
+0.03  (+4%)
Previous Close 0.71
Open 0.7
Price To Book 5.69
Market Cap 13,363,960
Shares 18,059,406
Volume 69,793
Short Ratio 5.57
Av. Daily Volume 86,068
Stock charts supplied by TradingView

NewsSee all news

  1. Navidea Biopharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Chief Executive

  2. Navidea Biopharmaceuticals Announces Receipt of Notice of Award

    Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced receipt of the Notice of Award

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved March 13, 2013.
Lymphoseek
Lymphatic-tissue tracing agent
Phase 3 - seeking partner to continue development
NAV4694
Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Approved June 13, 2014.
Lymphoseek
Head and Neck Cancer
Phase 2b trial is enrolling.
NAV3-31 (TC99m-tilmanocept)
Rheumatoid arthritis

Latest News

  1. Navidea Biopharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Chief Executive

  2. Navidea Biopharmaceuticals Announces Receipt of Notice of Award

    Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced receipt of the Notice of Award